- cross-posted to:
- news@beehaw.org
- medicine@mander.xyz
- cross-posted to:
- news@beehaw.org
- medicine@mander.xyz
cross-posted from: https://mander.xyz/post/11304633
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
Oh, the patent expired? No problem, we’ll just methylate the structure, see that it makes no difference and put it out on the market as a new drug. Or maybe take the active part of a racemic mixture and half the dosage. Same drug double the patent. Semisynthetic insulin is even worse in that regard.